Trial Profile

A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Napabucasin (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
Indications Adenocarcinoma; Colorectal cancer
Focus Registrational; Therapeutic Use
Acronyms CanStem303C
Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology

Most Recent Events

03 Jul 2021 Overall survival results presented at the 23rd World Congress on Gastrointestinal Cancer
22 Jun 2021 Status changed from active, no longer recruiting to completed.
23 May 2021 This trial has been completed in Belgium and Netherlands, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com